HELPING TO NAVIGATE YOUR NEW NORMAL.

For Patients For Healthcare Professionals

IDENTIFYING RESIDUAL AND RECURRENT DISEASE IN COLORECTAL CANCER (CRC) PATIENTS

Should you consider COLVERA™?

There are approximately 1,000,000 colorectal cancer (CRC) survivors in the United States. Of the 140,000 newly diagnosed patients each year, 30-50% will experience a recurrence, with the majority developing within the first 2 to 3 years of initial treatment.1,2 Although, the risk of recurrence varies by stage at time of diagnosis, more treatment options may be available when recurrence is detected early.

COLVERA is a qualitative blood test designed to detect residual and recurrent colorectal cancer, giving you and your healthcare provider additional information during your follow-up visits.

In a head to head clinical study, COLVERA detected twice the number of recurrent CRC cases compared to CEA. Of 122 patients who were tested after completion of their initial therapy, 28 patients developed a recurrent disease confirmed by CT scan. COLVERA detected recurrence in 19 of the 28 patients compared to only 9 of 28 patients detected by CEA.1

COLVERA is designed to fit into your routine recurrence monitoring schedule and can be ordered and performed with or without CEA, providing additional information that may identify residual or recurrent disease before symptoms are present and cancer has spread to other areas of the body.

Recurrence monitoring helps to increase the likelihood of identifying CRC recurrence when more treatment options are available. It is important to talk to your doctor if COLVERA is right for you.

About colorectal cancer

Colorectal cancer is the third most common cancer diagnosed, and the second leading cause of cancer related deaths in both men and women in the United States. This year, an estimated 140,000 people will be diagnosed with CRC, with approximately 50,000 people succumbing to the disease.2

Risk Factors:

  • Men and women age 50 and older
  • Family history of colon cancer
  • History of colon or rectal polyps
  • Inflammatory bowel disease (Crohn’s or ulcerative colitis)
  • Familial adenomatous polyposis (FAP)
  • Hereditary non-polyposis colon cancer
  • Obesity
  • Smoking
  • Heavy alcohol use
  • Racial and ethnic background
  • Men and women age 50 and older
  • Family history of colon cancer
  • History of colon or rectal polyps
  • Inflammatory bowel disease (Crohn’s or ulcerative colitis)
  • Familial adenomatous polyposis (FAP)
  • Hereditary non-polyposis colon cancer
  • Obesity
  • Smoking
  • Heavy alcohol use
  • Racial and ethnic background

Answers to common questions

What is COLVERA?
COLVERA is a blood test that may help detect colorectal cancer (CRC) recurrence. With COLVERA it may be possible to identify CRC recurrence in advance of symptoms, and possibly before other tests indicate recurrence.
How does COLVERA work?
COLVERA is designed to identify small amounts of altered DNA which may leak from a tumor into the bloodstream, called circulating tumor DNA or ctDNA. COLVERA detects the presence or absence of two genes in ctDNA, (BCAT1 and IKZF1), that are often associated with CRC growth.  While COLVERA detects changes found in most recurrent tumors, COLVERA may not be positive in all patients. COLVERA does not identify DNA changes that you may have inherited from your parents or pass on to your children.
What is the difference between COLVERA and carcinoembryonic antigen (CEA)?
COLVERA identifies the presence of two altered genes, (BCAT1 and IKZF1),in small fragments of DNA material that leak from a tumor into the blood stream, called circulating tumor DNA or ctDNA. CEA measures the amount of a protein that may appear in the blood of a patient with colorectal cancer. Although CEA has been used for over three decades to monitor patients, the test is not positive in many patients with cancer and may yield false positive results that can be caused by smoking and other non-cancer conditions. Head-to-head clinical evaluation in a recently published study showed that COLVERA detected twice as many recurrent colorectal cancers as CEA.
How can I get tested with COLVERA?
If your healthcare provider determines that COLVERA is right for you, your provider can order the test during your follow up office visit. Your blood can be drawn in office during your follow up appointment or at a Quest Diagnostics® Patient Service Center (PSC) near your provider’s office.
Can blood be drawn in my physicians office?
Yes. Blood can be conviently drawn in office during the time of your follow up appointment.
Do I need to fast before having my blood drawn?
There is no need to change or modify your diet for testing.
What is the specimen type required for testing?
COLVERA only requires two 9-10 mL tubes of whole blood.  This is equivalent to about 1.5 tablespoons of blood.
How long does it take to receive my results?
Your healthcare provider will receive your test results from the Clinical Genomics Laboratory within 7-12 days.
How is COLVERA reported?
COLVERA results are reported as positive or negative.

Social Icons

Facebook Twitter LinkedIn

Copyright © 2018 Clinical Genomics Technologies Pty Ltd. All Rights Reserved.